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Background: IBM’s Watson for Oncology (WFO) is an artificial intelligence tool that trains
by acquiring data from the Memorial Sloan Kettering Cancer Center and learns from test
cases and experts. This study aimed to analyze the adequacy and effectiveness of WFO in
determining the treatment method for patients with thyroid carcinoma.
Materials and Methods: We retrospectively enrolled 50 patients with thyroid cancer
who underwent surgery in 2018 and entered their clinical data into WFO. The WFO
treatment recommendations were compared with the surgical procedures and
recommended treatments performed according to the Korean Thyroid Endocrine
Surgery Association guidelines.
Results: The overall concordance rate between WFO-recommended treatments and
actual surgical treatments was 48%, and for patients with stage I, II, and III disease, these
rates were 52.4, 50, and 16.7%, respectively. A lower concordance rate was observed
with respect to treatment for advanced thyroid cancer.
Conclusion: WFO is a useful clinical aid but must be used with caution. A surgeon’s
decision takes precedence over WFO recommendations in the treatment of advanced
thyroid cancer.
Keywords: thyroid cancer, Watson for Oncology, IBM, artificial intelligence, treatment recommendationINTRODUCTION
Thyroid cancer has a high incidence worldwide. However, thyroid cancer patients have a relatively
good prognosis due to a low recurrence rate and high survival rate (1–3). Currently, several
recommendations from the American Thyroid Association (ATA), Korean Thyroid Association,
and Korean Association of Thyroid and Endocrine Surgeons (KATES) are cited in Korea (4–6). The
contents of these recommendations are comparable to a certain extent.Abbreviations: ATA, American Thyroid Association; AUC, Area under the curve; KATES, Korean Association of Thyroid
and Endocrine Surgeons; MSKCC, Memorial Sloan Kettering Cancer Center; WFO, Watson for Oncology.
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States) is a clinical decision-support system created by IBM
and named after its founder, Thomas J. Watson (7). It mainly
cites the ATA guidelines to determine the appropriate thyroid
cancer treatment. This system uses machine learning to evaluate
the clinical factors in a case and determines how treatment
options can be identified from the collected data. Its prime
function is to recommend the appropriate treatment based on
the patient’s electronic medical records. For example, if a
patient’s medical records, genetic information, and operability
status are entered, WFO recommends a treatment that is verified
by oncologists at the Memorial Sloan Kettering Cancer Center
(MSKCC). Moreover, certain types of anticancer drugs or
combinations thereof and radiation and hormone therapies are
also recommended by this system (8). Additionally, WFO provides
evidence to support the credibility of its recommendations, and this
evidence is based on relevant literature, such as studies and
associated data (9). When a doctor selects a treatment, WFO
provides the rate of survival, incidence of side effects, and other
related treatment information, helping the doctor assess the overall
effectiveness and treatment risk. In agreement with the MSKCC,
this technology has provided evidence-based treatment
recommendations for cancer patients since 2012 (10), and
currently, its applicability extends to various types of cancers such
as lung, breast, colorectal, and stomach cancers (11).
This study aimed to analyze the adequacy and effectiveness of
WFO by comparatively analyzing its recommendations with
those based on the KATES guidelines.MATERIALS AND METHODS
Patients
Clinical data from 50 patients diagnosed with thyroid cancer
between January 1, 2018, and December 31, 2018, at National
Health Insurance Ilsan Hospital were entered into WFO. These
patients had undergone surgical treatment following
recommendations by the KATES. The data included
demographic information such as sex and age; results of
medical imaging, nuclear medicine, pathology, and blood
testing; and information regarding surgical findings and
methods. These data were abstracted from the electronic
medical records and entered manually into WFO. This study
was approved by the Institutional Review Board of the National
Health Insurance Service Ilsan Hospital (IRB No. 2019-01-024).Watson For Oncology
WFO treatment recommendations are divided into three groups
with corresponding color-coded labels: green indicates
“recommended” based on strong evidence; orange indicates
“for consideration” implying that oncologists can consider the
treatment as an appropriate alternative based on their clinical
judgment; and red indicates a “not recommended” treatment due
to certain contraindications or lack of strong evidence of use.Frontiers in Endocrinology | www.frontiersin.org 2The Korean Association of Thyroid and
Endocrine Surgeon (KATES) Guideline
The extent of surgical procedure suitable for differentiated
thyroid carcinoma (DTC) is as follows: In the case of
micropapillary thyroid cancer of less than 0.5 cm, the surgery
timing can determine by selectively providing sufficient
information to the patient and observing for a certain period.
The initial surgical procedure of patients with DTC of >1 cm is
strongly recommended to perform total thyroidectomy or near-
total thyroidectomy. It is strongly recommended to perform total
thyroidectomy or near-total thyroidectomy for initial surgery in
patients with gross extrathyroidal extension, clinical evidence of
any lymph node metastasis, or distant metastasis. Thyroid
lobectomy is actively recommended for patients with unifocal
DTC of <1 cm without a personal history of radiation therapy to
the head and neck and familial DTC within the first generation,
limited within the thyroid gland, and no clinically detectable
cervical nodal metastases.
Lymph node dissection in DTC is as follows: If cervical lymph
node metastasis is clinically suspected, therapeutic central
compartment lymph node dissection (CCND) should be
performed. In the case of T3 or T4 lesions, under 15 years of
age or over 45 years of age, multiple lesions, extrathyroidal
extension, and lateral cervical lymph node metastasis,
prophylactic CCND may be considered even if the central
lymph node metastasis is not clinically suspected.
Concordance
The final comparison target was the surgical treatment suggested
by KATES and WFO. Concordance was defined as a match
between the surgeon’s treatments that were performed based on
recommendations by the KATES (4) and the WFO’s
“recommended” category of surgical treatments. If the
surgeon’s treatment was included in the WFO’s “considered”
and “not recommended” categories, it was considered a
non-concordance.
The null hypothesis was that WFO’s area under the curve
(AUC) for the standard treatment is 0.75, while the alternative
hypothesis assumed that if the AUC of WFO for the standard
treatment is 0.75 or more, the AUC of WFO is 0.95. Therefore,
for a type I error of 0.05 and a power of 0.8, the required number
of patients would be approximately 40. Further, considering a
dropout rate of 20%, 50 participants would be needed to test this
hypothesis. As this sample size was achievable within the
affiliated institution, the study was not expanded to other
research institutes.RESULTS
Patient Characteristics
Among the 50 patients recruited in this study, the majority were
women (41, 82%), and the mean tumor size was 0.9 cm. All
patients had been diagnosed with papillary thyroid cancer: 32
patients (64%) had bilateral lobe invasion and 29 (58%) had
extracapsular involvement. The tumor-node-metastasis stageMarch 2021 | Volume 12 | Article 585364
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system by the American Joint Committee on Cancer (12). T1a,
T1b, and T2 disease was observed in 32 (64%), 14 (28%), and 4
(8%) patients, respectively; N0, N1a, and N1b disease was
observed in 30 (60%), 17 (34%), and 3 (6%) patients,
respectively. There were 42 patients (84%) with stage I disease,
2 patients (4%) with stage II disease, and 6 patients (30%) with
stage III disease (Table 1).
Concordance Analyses
The concordance rates between the WFO-recommended and
KATES-recommended surgical treatment options were analyzed
according to the following groups: “recommended,” “for
consideration,” and “not recommended.” Overall, the surgical
treatments were “recommended” in 24 cases (48%), “for
consideration” in 2 cases (4%), and “not recommended” in 24
(48%) cases. The postoperative final results were consistent with
the preoperative predictions in all concordant patients. OnFrontiers in Endocrinology | www.frontiersin.org 3further analyses, the surgical treatments were “recommended”
in 22 cases (52.4%), “for consideration” in 1 case (2.4%), and “not
recommended” in 19 cases (45.2%) byWFO among patients with
stage I cancers. Among patients with stage II cancer, the surgical
treatment was “recommended” in 1 case (50%) and “not
recommended” in 1 case (50%). Finally, among patients with
stage III cancer, the surgical treatment was “recommended” in
one case (16.7%), “for consideration” in 1 case (16.7%), and “not
recommended” in four cases (66.7%) by WFO (Figure 1).DISCUSSION
Artificial intelligence has substantially greater memorization
capabilities than the human brain; it can quickly collect and
sort the stored information, such as diagnostic radiology
applications and applications of pathology imaging systems, to
obtain precise conclusions rapidly (13, 14). WFO was created to
serve as a support system that uses vast amounts of medical
evidence to aid doctors in treatment planning. Further, it can
markedly shorten the time spent by inexperienced surgeons in
consulting relevant literature, improving their ability to make
accurate diagnoses and prompt treatment recommendations.
In this study, 24 of 50 treatment methods used were
consistent with those recommended by WFO, and higher
stages of thyroid cancer were associated with a lower
concordance rate. Non-concordance between the treatment
methods of WFO and KATES is shown in Table 2. Non-
concordance between the methods considered category by
WFO and the KATES was observed in 2 cases. In one non-
concordant case, WFO recommends active surveillance, but
thyroid lobectomy was performed with careful explanation
because the pathological result in repeated fine-needle
aspiration was category III of the Bethesda system (15). Final
pathological result is papillary thyroid carcinoma. In another
case, total thyroidectomy was recommended by WFO because of
clinically suspected extrathyroidal extension. But unilateral
thyroidectomy was performed because the extrathyroidal
extension was not observed during the operation.
Non-concordance between the methods recommended
category by WFO and the KATES was observed in 24 cases.TABLE 1 | Patient characteristics.
Characteristics Total N = 50, No. (%) or
mean
Age, year (range) 47.5 (25–77)
Female/Male 41/9 (82%/18%)







Bilateral involvement 17 (34%)
Extrathyroidal extension 29 (58%)
TNM stage (AJCC 8th
edition)
T stage T1a 32 (64%)
T1b 14 (28%)
T2 4 (8%)
N stage No 30 (60%)
N1a 17 (34%)
N1b 3 (6%)
TNM stage I 42 (84%)
II 2 (4%)
III 6 (12%)AJCC, American Joint Committee on Cancer; TNM, tumor-node-metastasis.FIGURE 1 | Concordance between the Watson for Oncology-recommended treatment and actual surgical treatment based on the Korean Association of Thyroid
and Endocrine Surgeons guidelines.March 2021 | Volume 12 | Article 585364
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surveillance and no surgical procedure due to the small tumor
size (0.4 cm) and lack of clinical symptoms. However, this
patient had undergone unilateral thyroidectomy due to the risk
factor of family history (16). An explanation for this non-
concordance could be that information regarding risk factors
such as family history were not entered in the corresponding data
field of the patient’s medical records and examination results.
In 7 patients, total thyroidectomy was recommended by WFO
because of clinically suspected extrathyroidal extension. As per
ATA and KATES guidelines, thyroid cancer patients with tumors
sized > 4 cm or with gross extrathyroidal extension should
undergo an initial surgical procedure including a near-total or
total thyroidectomy and gross removal of all primary tumors (5).
However, unilateral thyroidectomy was actually performed
because extrathyroidal extension was not observed during the
operation or on postoperative histopathological examinations. A
surgeon with this experience can make appropriate changes to the
pre-determined treatment method according to operative findings.
However, if the surgeon does not have this experience and relies
solely onWFO recommendations for thyroidectomy, it can lead to
unnecessary surgery that reduces the patient’s quality of life.
WFO did not recommend central compartment lymph node
dissection in 16 patients because no lymph nodes with suspected
metastasis were observed preoperatively. However, during the
operation, an enlarged central lymph node that indicated
metastasis was observed, and a thyroidectomy with central
compartment lymph node dissection was performed. Nodal
metastasis was confirmed on permanent histopathological
examination. In patients with clinically apparent lymph node
metastasis, central compartment lymph node dissection improves
survival and lowers the risk of recurrence (17). However, in the
absence of clinically apparent lymph node metastasis, several
guidelines, including those of WFO, do not recommend
performing dissection prophylactically (18, 19). Therefore,
inexperienced surgeons solely relying on WFO recommendations
may inadvertently neglect metastatic lymph nodes.
From another perspective, confirming seen in preoperative
imaging studies (CT, US) is essential during surgery. However,Frontiers in Endocrinology | www.frontiersin.org 4image studies cannot completely determine whether there is
extrathyroidal extension or lymph node metastasis. Therefore,
Non-concordance in determining the extent of surgery due to
extrathyroidal extension or lymph node metastasis may be due to
imaging studies’ limitations, not the WFO itself.
In 6 stage III patients, 5 showed non-concordance. The
average age of 5 patients was 57.5 years, four patients with T1b
and 1 with T2 each, and all patients with N1a. there were no
particular differences from other stage except age. Four cases
showed non-concordance depending on whether CCND was
performed or not. In another case, WFO recommends active
surveillance, but thyroid lobectomy was performed.
Evidence-based medicine forms the backbone of modern
medicine and entails that patients be treated according to a clear
medical rationale, unlike that in the past, when the treatment
heavily relied on the intuition or experience of the doctor. WFO is
a technology that uses a clear medical rationale and has the
capability to learn and recall all of the abundant and constantly
updated evidence. Nonetheless, the planned treatment or surgical
extent may change according to intraoperative findings in some
cases, reinstating the importance of the surgeon’s judgment.
There are several limitations to our study. First, it was a
retrospective observational study that lacked controls; this made
the results potentially vulnerable to the influence of unmeasured
factors. Second, the group of patients with stage I cancer was
considerably larger than the other groups. This study is a
preliminary study, conducted only in a group of 50 patients. In
the clinical field, there are more patients in stage I than stage II
and stage III, but the results will be more accurate if more
patients are studied in the future. Third, the results may vary if
different versions of WFO or the KATES guidelines are used.
Updated versions of the these WFO and KATES guidelines
should be validated in further research.
In conclusion, WFO is useful as an assistive tool for doctors.
However, it must be used with caution because the WFO
recommended treatment for patients with advanced thyroid
cancer may not be the most appropriate approach. Therefore, the
surgeon’s judgment gains precedence over WFO recommendations
in determining the treatment method for patients with advanced
thyroid cancers. In the future, a multicenter study should be
conducted to investigate the adequacy and Effectiveness of WFO
in the treatment of thyroid carcinoma.DATA AVAILABILITY STATEMENT
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16AUS, atypia of undetermined significance; FNA, fine needle aspiration; AS, active
surveillance; ETE, extrathyroidal extension; TT, total thyroidectomy; CCND, central
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